Davita Inc vs Palantir Technologies Inc — how do they compare? Davita Inc trades at $232 (market cap $14.92B), while Palantir Technologies Inc trades at $134.11 (market cap $320.57B). The key difference: Palantir Technologies Inc is far larger — about 21.5× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| DVA | PLTR | |
|---|---|---|
Market Cap | $14.92B | $320.57B |
Sector | Health | Technology |
52-Week High | $235.71 | $207.18 |
52-Week Low | $103.87 | $107.27 |
Enterprise Value | $27.47B | $312.75B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
PLTR trades at $130.05, up 2.57% today, with technical indicators showing neutral signals amid bearish moving averages. The company demonstrates exceptional fundamental strength with 2025 revenue of $4.48B and net income of $1.63B, representing a 36.3% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.33 surpassing the $0.28 estimate. Analyst consensus remains positive with a $185.75 price target, though valuation metrics remain elevated at P/E of 146.11 and P/S of 63.97.
PLTR presents a growth opportunity with strong AI positioning and expanding profitability, but faces significant valuation risk and competitive pressures. The stock's premium multiples require sustained high growth to justify current levels, while upcoming Q2 2026 earnings on August 3 will be critical for validating the growth trajectory. Institutional sentiment remains divided with 46% buy ratings versus 42% hold recommendations.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →